CD Biosynsis offers cutting-edge CHO (Chinese Hamster Ovary) Cells Base Editing Services, enabling highly precise, single-nucleotide substitutions in this premier mammalian host. CHO cells are the industry standard for producing complex therapeutic proteins and monoclonal antibodies (mAbs). Base Editing is a revolutionary technology that allows for the direct conversion of specific nucleotide pairs (e.g., C to T or A to G) without creating a DNA double-strand break (DSB). This method is highly desirable in mammalian hosts as it significantly increases editing efficiency and minimizes unwanted insertion/deletion (indel) byproducts associated with the NHEJ pathway. Our services are essential for optimizing product quality (e.g., glycoprofile optimization), enhancing cell fitness by editing promoters and UTRs, and introducing beneficial amino acid changes in host enzymes crucial for bioprocessing performance.
Get a QuoteTraditional CRISPR/Cas9 editing in CHO cells relies on the error-prone NHEJ pathway for simple knockouts and the low-efficiency HDR pathway for precise edits. Base Editing bypasses these limitations by employing a Cas9 nickase fused to a base deaminase. This system enables irreversible chemical conversion of a base within a precise editing window, eliminating the need for a DSB and drastically reducing indel formation. This capability is critical for optimizing the host's PTM machinery, increasing the expression of transport genes, and fine-tuning cell cycle regulators, ensuring maximum yield of active, high-quality therapeutic proteins.
Rational gRNA Design
Computational design of gRNAs to position the target base within the editor's optimal editing window, maximizing on-target conversion efficiency in the CHO genome.
Nuclear Targeting & Timing
Optimization of NLS-fused Base Editor delivery (RNP preference) and transient expression timing to minimize off-target editing events in the mammalian cell line.
Allelic Optimization
Strategies for editing multiple target gene alleles in the pseudo-tetraploid CHO genome, ensuring uniformity and complete functional modification of the host cell population.
Cytosine Base Editors (CBE)
Systems (e.g., BE3, BE4) equipped with NLS tags for C to T conversion, often used for introducing targeted stop codons or promoter-disrupting mutations.
Adenine Base Editors (ABE)
Systems enabling the conversion of A to G, critical for introducing specific amino acid changes or modifying polyadenylation signals to enhance mRNA stability.
RNP or Lentiviral Delivery
Delivery of the NLS-Base Editor and gRNA via optimized Ribonucleoprotein (RNP) complexes for transient editing, or lentivirus for stable genomic integration of the editor.
Glycosylation Profile Tuning
Single-base edits to key glycosylation genes (e.g., GNAT) to fine-tune activity, ensuring desired human-like N-glycan homogeneity for therapeutic mAbs.
Enhanced Cell Viability
Precision editing of pro-apoptotic genes (e.g., Bax, Bak) to safely reduce their activity (hypomorphic mutation), extending cell culture longevity and final product titer.
Metabolic Tuning (Lactate/Ammonia)
Introducing subtle point mutations into enzymes like LDHA or GS to safely reduce metabolic byproduct formation without causing cell lethality.
A systematic process for achieving precise substitution and stable cell line isolation.
1. Rational Design & RNP Preparation
2. Transfection & Editing
3. Single Cell Cloning & Screening
4. Clone Verification & Delivery
Identify optimal single-base substitutions. Design gRNAs to place the target base within the editor's optimal deamination window.
Prepare the Cas9 nickase/deaminase Base Editor RNP complex for transient delivery.
Design selection strategy (e.g., drug resistance marker) to enrich for edited cells.
Deliver the RNP complex into the CHO host cell line via optimized electroporation or lipofection protocols.
Culture cells to allow the base conversion and repair mechanism to finalize the genomic edit.
Apply antibiotic selection to enrich for stable editing events.
Genotype verification via Sanger sequencing of the edited locus to confirm desired single-base substitution in all functional alleles.
Phenotypic validation of the final clone for titer, stability, and product quality over multiple passages.
Delivery of the verified CHO master cell bank (MCB) and comprehensive documentation.
DSB-Free Precision
Avoids DNA double-strand breaks, resulting in ultra-high editing efficiency for single-base changes and minimizing undesirable indel byproducts, maximizing safety for industrial strains.
Allelic Uniformity
Strategies optimized for the complex CHO genome ensure highly consistent editing across multiple alleles, guaranteeing a uniform, stable, and functionally optimized cell population.
Product Quality Tuning
Ideal tool for fine-tuning complex traits like glycosylation and product aggregation by introducing subtle point mutations into host cell protein (HCP) or PTM pathways.
RNP Delivery Focus
Preference for RNP delivery ensures transient Cas9 activity and low off-target editing, maximizing safety and regulatory acceptance for the final CHO Master Cell Bank (MCB).
1. Why is Base Editing better than Cas9/HDR for single-base changes in CHO cells?
Base Editing performs the base conversion chemically without a DSB, achieving much higher efficiency and drastically reducing indels. Cas9/HDR is often inefficient for point mutations in CHO cells.
2. Can Base Editing be used to optimize protein glycosylation?
Yes. It is ideal for introducing single-base changes into glycosylation enzymes (e.g., GNAT) to subtly alter their activity, ensuring the therapeutic mAb product has the desired human-like glycan profile (quality tuning).
3. How do you address the complexity of the CHO pseudo-tetraploid genome?
We use high-efficiency editors and strategies designed to simultaneously edit all functional alleles of the target gene, ensuring uniformity and preventing residual wild-type expression that could compromise product quality.
4. Can you use Base Editing to reduce lactate production?
Yes. We introduce subtle point mutations into metabolic enzymes like LDHA (lactate dehydrogenase) to safely reduce their activity (hypomorphic mutation), minimizing toxic byproduct accumulation without causing cell lethality.
5. What is the role of the Nuclear Localization Signal (NLS)?
The NLS tag on the Base Editor is essential for transporting the large enzyme complex across the nuclear membrane and into the CHO cell nucleus, where the genomic DNA is located.
6. What delivery methods are used for the Base Editor?
Our preference is Ribonucleoprotein (RNP) delivery via electroporation for transient, high-efficiency editing. Lentiviral delivery is used for projects requiring stable genomic integration of the editor itself (e.g., for long-term functional studies).
7. How is the editing verified across all alleles?
Verification requires high-resolution methods like deep sequencing (NGS) or Sanger sequencing of cloned PCR products to confirm that the desired base change has occurred in all functional alleles of the target gene.
8. Can Base Editing be used to integrate large DNA fragments?
No. Base Editing is limited to single-base changes. For large fragment insertion (Gene Knock-in), the standard CRISPR-Cas9 system coupled with the Homology-Directed Repair (HDR) pathway is required.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.